Sai Parenterals is a pharmaceutical company that has transformed itself from a contract manufacturer into a global, IP-led platform - it doesn’t just make medicines for others, it now owns the recipes, the regulatory approvals, and the last-mile distribution in some of the world’s most tightly regulated markets. The business was founded in 2001, but its current shape was forged in 2016 when the promoters took full control and, more decisively, in late 2025 when it acquired a controlling stake in Australia’s Noumed Pharmaceuticals, gaining a direct pipeline into Australian and New Zealand pharmacy shelves. The recurring approach is to stitch together the entire value chain - from in-house R&D and manufacturing in India to marketing and distribution in developed countries - so that it captures value at every step, not just the factory gate.
Business segments
Three engines, tightly coupled - a regulated-market platform in Australia and New Zealand that owns the customer relationship, a CDMO export business that supplies complex injectables and oral drugs to multinationals, and a domestic branded-formulation base that provides stability and a portfolio of 302 products.
1. Australia & New Zealand platform: the IP and distribution engine
Through its Noumed subsidiary, Sai owns one of Australia’s largest private-label OTC portfolios and a turnkey solution that handles everything from manufacturing to pharmacy delivery - making it the only organization in the country offering that full service to multinational customers right now.
- Turnkey partner to multinationals - Noumed owns the intellectual property, makes the product, releases it, and distributes it on behalf of the client, a complete chain that no other organization in Australia currently provides. It supplies Novartis with the Demazin and Duro-Tuss brands, and is the exclusive OTC supplier to one of Australia’s leading multi-billion-dollar pharmacy chains under a contract that adds 12 new products every year.
- Shelf space in 2,100 pharmacies - Noumed’s two largest customers are Wesfarmers Health (which runs the Priceline and Pharmacy Health banners) and the EBOS Group (Terry White Chemmart and Pharmacy Choice), together covering more than a third of Australia’s 5,500 pharmacies. That gives Sai a distribution footprint that would take a new entrant years to replicate.
- A dossier vault that cuts launch times in half - the acquisition brought 451 IP dossiers that Sai can leverage across multiple export markets, shrinking the typical product-launch timeline from 18-24 months down to 6-9 months. Five more dossiers were added in Australia in the fourth quarter of FY26 alone.
- Building Australia’s largest and most modern plant - an Adelaide manufacturing facility for tablets, liquid orals, and nasal sprays is on track for completion in Q4 FY27, backed by a grant of almost AUD 20 million from the Federal Australian Government. Once running, it will let Sai progressively bring in-house a large chunk of the production that Noumed currently outsources to Indian contract manufacturers, tightening margins and control.
2. CDMO export business: the complex-manufacturing engine
Sai serves as an end-to-end contract development and manufacturing partner for multinational pharma companies, backed by 599 approved product registrations in regulated markets and a ₹440 crore capex program to upgrade its Indian plants to EU-GMP standards.
- Long-term contracts with locked-in demand - the CDMO business operates under exclusive, long-term supply agreements with customers in Australia, New Zealand, and the Philippines, and more than half of the group’s consolidated revenue comes from these regulated-market contracts. That shifts the business from spot manufacturing to predictable, relationship-based revenue.
- Bought, not just built - the company acquired its TGA-approved Unit III for ₹24 crore in FY2022 and its PIC/S-approved Unit IV for ₹11 crore in FY2023, both as assets that generated no revenue before the purchase. That is how Sai added regulatory certifications and capacity at a fraction of the time and cost of greenfield construction.
- An R&D engine feeding the pipeline - the 75%-owned subsidiary SP Analytics drives formulation development and regulatory filing, with 67 dossiers currently under development and expected to be commercialized during FY27 and FY28. A new R&D centre in India, costing ₹18 crore, will add 20 scientists to accelerate new product launches for export markets.
3. Domestic branded formulations: the stable home base
A portfolio of 302 complex products across all major dosage forms, sold under the company’s own brands in India, provides a steady operating foundation and a product library that feeds the export pipeline.
- Full dosage-form coverage - the domestic business makes liquid and dry-powder injectables, tablets, capsules, liquid orals, sprays, ointments, and dry syrups, with a therapeutic focus on critical-care injectables and penicillin-based therapies. That breadth means the company can cross-sell multiple formats to the same hospital or pharmacy customer.
- A second manufacturing base in Ongole - the wholly owned subsidiary Revat Laboratories runs a GMP-certified facility in Andhra Pradesh that produces tablets, capsules, and liquid orals, adding capacity beyond the Hyderabad cluster. Revat was founded by the promoters and brought fully into the group in FY2024 for ₹28 crore.
- Customer relationships that anchor the group - the branded business builds direct relationships with Indian doctors, hospitals, and pharmacies, creating a commercial foundation that complements the CDMO and export engines rather than competing with them.
Group structure and partners
Sai Parenterals sits at the centre of a structure that separates Indian manufacturing, Singapore-based holding, and Australian/New Zealand commercial operations - with two of Australia’s top-20 ASX-listed companies as its anchor pharmacy customers.
- The parent company, Sai Parenterals Limited (India), houses the branded generic and CDMO businesses, while its wholly owned subsidiary Revat Laboratories runs the Ongole plant.
- A Singapore subsidiary, Sai Parenterals Pte Limited, acts as the holding vehicle for cross-border transactions and owns 74.64% of Noumed Pharmaceuticals in Australia, which in turn fully owns Noumed Pharmaceuticals in New Zealand.
- The R&D subsidiary SP Analytics is 75% owned by the parent, keeping formulation development closely tied to the group while allowing for focused investment.
- In Australia, Noumed’s key partners are Wesfarmers Health and the EBOS Group - both top-20 ASX-listed firms - whose pharmacy banners give Sai access to 2,100 of the country’s 5,500 pharmacies. The Adelaide factory expansion is co-funded by a nearly AUD 20 million grant from the Federal Australian Government.